Stryker (NYSE:SYK) Given New $379.00 Price Target at BTIG Research

Key Points

• BTIG Research cut its price target on Stryker from $397 to $379 but kept a "buy" rating, while the analyst consensus remains a "Moderate Buy" with an average target around $418.26.
• Q1 results missed expectations — Stryker reported $2.60 EPS (vs. ~$2.98 expected) and $6.02B revenue (vs. ~$6.34B) — yet management maintained FY‑2026 guidance (adjusted EPS $14.90–$15.10 and 8–9.5% organic sales growth) and said operations have largely recovered from a cyber incident.
• Notable insider and institutional moves: Director Ronda E. Stryker sold 250,000 shares for about $90.7M; insiders own 4.6% of the company and roughly 77% of shares are held by institutions.

Stryker (NYSE:SYK - Get Free Report) had its target price cut by investment analysts at BTIG Research from $397.00 to $379.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the medical technology company's stock. BTIG Research's price objective suggests a potential upside of 20.46% from the company's current price.

A number of other equities research analysts have also recently commented on the company. Raymond James Financial upgraded Stryker from a "market perform" rating to an "outperform" rating and set a $418.00 target price on the stock in a research report on Tuesday, January 6th. Truist Financial dropped their target price on Stryker from $395.00 to $380.00 and set a "hold" rating on the stock in a research report on Wednesday, April 15th. The Goldman Sachs Group dropped their target price on Stryker from $403.00 to $357.00 and set a "neutral" rating on the stock in a research report on Thursday, April 9th. Evercore set a $390.00 target price on Stryker in a research report on Monday, January 5th. Finally, Citigroup dropped their target price on Stryker from $420.00 to $385.00 and set a "buy" rating on the stock in a research report on Tuesday, April 7th. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $418.26.

Stryker Price Performance

NYSE:SYK opened at $314.64 on Friday. Stryker has a 52 week low of $311.31 and a 52 week high of $404.87. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $120.50 billion, a PE ratio of 37.46, a price-to-earnings-growth ratio of 1.84 and a beta of 0.92. The stock's 50-day moving average price is $345.67 and its 200-day moving average price is $356.95.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the business earned $2.84 earnings per share. Stryker's revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts expect that Stryker will post 14.91 EPS for the current fiscal year.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.60% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company's stock worth $11,917,396,000 after purchasing an additional 133,892 shares in the last quarter. State Street Corp lifted its stake in Stryker by 2.1% in the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company's stock worth $5,374,731,000 after purchasing an additional 311,507 shares in the last quarter. Geode Capital Management LLC lifted its stake in Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company's stock worth $2,636,238,000 after purchasing an additional 69,851 shares in the last quarter. Wellington Management Group LLP lifted its stake in Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company's stock worth $2,282,192,000 after purchasing an additional 1,198,665 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company's stock worth $2,342,987,000 after purchasing an additional 741,542 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Management kept FY‑2026 guidance intact — organic sales growth of 8%–9.5% and adjusted EPS of $14.90–$15.10, signaling confidence in medium‑term demand and execution. Stryker maintains 2026 outlook
• Positive Sentiment: Cash flow and GAAP net income showed strength (operating cash from ops surged year‑over‑year; reported profit rose to $745M), providing balance‑sheet flexibility. Q1 results: cash flow & net income up
• Positive Sentiment: Company says it has largely recovered operationally from the cyber incident, which management says disrupted the quarter but is being contained. That supports the decision to keep guidance. Stryker reports first quarter 2026 operating results
• Neutral Sentiment: Full Q1 press conference transcript and management commentary are available for details on recovery timing, regional trends and product‑line performance — useful for assessing forward visibility. Q1 2026 press conference transcript
• Negative Sentiment: Q1 adjusted EPS of $2.60 missed the consensus (~$2.98) and revenue of $6.02B fell short of estimates (~$6.34B), a headline miss that pressured the stock. Q1 earnings snapshot / consensus miss
• Negative Sentiment: Management cited softer demand for implants and complex‑procedure devices (orthopaedics, spine) and adjusted operating margin contraction (~180 bps), suggesting near‑term revenue headwinds even as recovery from the cyber event continues. Reuters: misses estimates on muted demand

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.